Lyon, France – Octobre 06, 2005 – Flamel Technologies S.A.(NASDAQ: FLML) today announced that Michel Finance has joined its senior management team as Flamel's Executive Vice President and Chief Financial Officer. He will play an important role in other management responsibilities within the company, including legal affairs and investors relations, and he will participate in business development activities of Flamel .

Michel Finance, 48 years old, is a French and Canadian citizen, He is graduated from EM Lyon and is a French CPA.

Mr. Finance brings extensive experience in the pharmaceutical sector, having served in his last position as Senior Vice President and Corporate Controller for Aventis Group, reporting to the Vice Chairman of the Board. In this capacity, Michel oversaw all corporate and functional controlling. His corporate responsibilities included consolidation, accounting research, management reporting and business analysis, corporate accounting, resource allocation, business plan and cash flow management. He also supervised the finance functions of the Europe and Intercontinental regions.

Michel started with Aventis predecessor companies in 1986 after having spent 5 years as auditor at Coopers and Lybrand in Lyon. For the past 18 years, he has assumed increasing responsibilities in finance, information systems, operational and strategic planning. After joining Institut Mérieux in 1986, he worked on the acquisition of Connaught Laboratories. He then moved to Toronto (Canada) in 1990 as North America Chief Financial Officer for Pasteur Mérieux Connaught. In 1995, he became Chief Financial Officer of Pasteur Mérieux Connaught group in Lyon. At the creation of Aventis, he moved to Aventis Pharma headquarters in Frankfurt as Senior Vice President and Corporate Controller. In 2002, he became Senior Vice President and Corporate Controller of the Aventis Group.

"Mr. Finance's background in the pharmaceutical industry worldwide makes him an ideal addition to the Flamel team," remarked Stephen H. Willard, Flamel's Chief Executive Officer. "Together, we will build an infrastructure that will further drive Flamel's world-leading technology in the drug delivery field."

"I am thrilled to be joining a company with so many important potential growth drivers," said Mr. Finance. "Flamel's strength and partnerships support a wealth of potential innovative products which will utilize our two intellectual property platforms for drug delivery of proteins, peptides, and small molecules. The entrepreneurial culture of Flamel is exciting to me and I am eager to begin working with the rest of the team at the company."

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump® is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel's Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteins and peptides.

Contact:

Charles Marlio, Director of Strategic Planning and Investor Relations
FRANCE (011) 33-4-72-78-34-23
US (1) 202-862-8400
Fax: 202-862-3933
E-mail: Marlio@flamel.com

This document contains a number of matters, particularly as related to the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2004.